Bergen 21 November 2023 - Reference is made to the stock exchange announcement
published by BerGenBio ASA (the "Company") on 15 June 2023 regarding the
allocation of offer shares and warrants (the "Warrants") to certain primary
insiders and close associates of primary insiders of the Company in connection
with the June 2023 rights issue completed pursuant to a resolution by the
Company's annual general meeting on 22 May 2023. Reference is further made to
the Company's stock exchange announcement published on 15 November 2023
regarding the commencement of the first exercise period for the Warrants. Each
Warrant gives the holder a right to subscribe for one new share ("New Share") in
the Company. The Warrants are listed and tradable on the Oslo Stock Exchange
until 16:30 hours (CEST) on 8 April 2024 under the ticker code "BGBIS".

Today, the Company has been informed that the following primary insiders and
close associate has exercised all their respective Warrants on 20 November 2023:

  · Martin Olin (CEO): 1,000,000 Warrants, for the allocation of 1,000,000 New
Shares in the Company at a price per New Share of NOK 0.13.
  · Rune Skeie (CFO): 129,595 Warrants, for the allocation of 129,595 New Shares
in the Company at a price per New Share of NOK 0.13.
  · Anders Tullgren (chairman): 704,910 Warrants, for the allocation of 704,910
New Shares in the Company at a price per New Share of NOK 0.13.
  · Sally Bennett (board member): 157,413 Warrants, for the allocation of
157,413 New Shares in the Company at a price per New Share of NOK 0.13.
  · Debra Barker (board member): 155,513 Warrants, for the allocation of 155,513
New Shares in the Company at a price per New Share of NOK 0.13.
  · Svev AS (company wholly owned by board member Sveinung Hole): 1,000,000
Warrants, for the allocation of 1,000,000 New Shares in the Company at a price
per New Share of NOK 0.13.

Please see further details about the transactions in the attached forms.

The New Shares issued upon exercise of Warrants will be listed on the Oslo Stock
Exchange under ISIN NO 001 0650013 and ticker code "BGBIO". The New Shares will
be listed as soon as the New Shares have been registered in the VPS and the
Company has published a prospectus in relation to the listing of the New Shares,
approved by the Norwegian Financial Supervisory Authority (the "NFSA").

The New Shares may not be transferred or traded before they are fully paid, and
the New Shares will, if required, be placed on a separate ISIN pending approval
and publication of the listing prospectus for the New Shares.

Subject to timely payment of the subscription price for the New Shares on 4
December 2023, the Company expects the share capital increase pertaining to the
exercise of Warrants to be registered with the Norwegian Register of Business
Enterprises on or about 6 December 2023 and that the New Shares will be
delivered to the VPS accounts of the subscribers to whom they are allocated on
or about 7 December 2023.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.